FindTrial
Sign In

Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00530595
Enrollment
Unknown
Registered
2007-09-17
Start date
Unknown
Completion date
Unknown
Last updated
2007-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease

Keywords

hemodialysis

Brief summary

Cardiovascular disease is a leading cause of mortality in patients on hemodialysis therapy (HD), accounting for 30 to 50% of all death. Although angiotensin receptor blockers (ARBs) are effective for patients with diabetes and chronic kidney disease in reducing or preventing cardiovascular diseases, there has been no decisive study that demonstrated treatment with ARBs is effective in patients on HD.

Interventions

DRUGcandesartan or valsartan or losartan

Sponsors

Saitama Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* 30 to 80 years of age * Receiving hemodialysis at least 12 months and less than 5 years * Pre-dialysis systolic blood pressure was more than 160 mmHg, or more than 150 mmHg if the patients received antihypertensive agents.

Exclusion criteria

* Use of angiotensin receptor blocker or angiotensin converting enzyme inhibitor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026